Search
Searching Content indexed under Food and Drugs Law by LexOrbis ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Competitive Generic Therapy: Manna For Generic Companies
The US Food and Drug Administration (FDA) has over the years come up with initiatives to protect the interests of both the patented and generic drug manufacturers.
India
8 Aug 2019
2
Biosimilars- An Emerging Trend In Indian Pharma Industry
India released the draft regulatory guidelines for ‘Similar Biologics' at the BIO industry conference in Boston, USA, on 19 June 2012.
India
11 Jul 2019
3
Test For Determining Trademark Similarity For Nutraceutical Products Is The Same As The Test Applicable For Pharmaceutical
In a suit for trademark infringement and passing off filed by Sun Pharma Laboratories Ltd. for its mark GLOEYE against Ajanta Pharma Ltd, which was using GLOTAB, the Delhi High Court held that principles laid down in Cadila ...
India
10 Jun 2019
4
Race To The Generic Launch
This is not the first time that these pharma giants have tried hindering the process of generic drug development.
India
15 May 2019
5
No Price Control On New Drugs Patented In India
The new amendment in DPCO also exempts drugs for orphan diseases also known as orphan drugs from the price control mechanism.
India
8 Jan 2019
6
Bombay High Court Imposes Huge Exemplary Damages on Habitual Offenders
Bombay High Court in recent cases of habitual offenders has imposed huge exemplary cost on Defendants. In less than one month, there have been two cases where Bombay High Court has considered the Defendant's malafide actions and punished them monetarily.
India
26 Sep 2018
7
Indian Government prohibits 328 fixed dose combinations
The Ministry of Health and Family Welfare, Government of India vide Gazette notification nos. S.0.4379(E) to S.0.4706(E) dated 07.09.2018 has prohibited 328 Fixed Dose Combinations (FDCs) for manufacture, sale or distribution with immediate effect ..
India
21 Sep 2018
8
Yes To ‘Vanda' : Gateway To Personalised Treatment Patent!
Personalised treatment with customised medical treatment is fast growing area of health care.
India
21 Sep 2018
9
Online Pharmacies In India
Increased globalisation and health awareness, along with the ease with which patients can self-diagnose and -medicate, has led to the rise of online pharmacies.
India
15 Sep 2017
10
Cipla v Novartis: Import Qualifies As Working Of Patent
The Indian pharmaceutical industry is a major manufacturer of cost-effective generic drugs and is set to become the leading exporter of generic pharmaceutical products.
India
31 May 2017
11
New Drug Approval: Regulatory Scenario In India
Considering the Indian pharmaceutical industry is the third largest industry in terms of output, it is necessary to understand the regulatory scenario for the pharma sector...
India
29 Mar 2016
12
Sitagliptin Judgement: An Overview
In a recent, very intensely contested litigation between Merck Sharp and Glenmark Pharmaceuticals Ltd., the Hon'ble Delhi High Court delivered a much awaited judgement. In the suit Merck contended infringement of its Anti-diabetic drug Sitagliptin ..
India
5 Jan 2016
13
Cipla Seems To Be On The Skids
Earlier in the month of November, Indian generic drug maker Cipla Ltd. had requested the Central government to revoke five patents held by Swiss firm Novartis AG on respiratory drug Indacetorol, used for the treatment of Chronic Obstructive Pulmonary Disease (COPD) under the brand name ‘ONBREZ’.
India
22 Dec 2014
14
Compulsory Licence Decisions: A Comparative Study Of Facts
It is now been almost two years the first compulsory license was granted by the Controller General of India to Natco Pharma Ltd., an Indian generic drug manufacturer.
India
4 Mar 2014
15
Power Of Registrar To Accept Rectification Application During The Pendency Of Suit
Sec. 57 of the Trade and Merchandise Marks Act, 1958 gives power to registrar to rectify the register. However, the plain reading of this section gives rise to a conflicting situation in light of section 107 of the Act, which puts a bar on power of registrar in this regard.
India
14 Dec 2006
16
Widening Ambit Of Indian Intellectual Property Regime
The Scenario in the IPR sector has undergone vibrant change in the recent past. This change has not been restricted to the pharmaceutical sector alone, but has extended itself to other systems of Intellectual Property.
India
 
13 Jul 2006
17
Passing Off Pharmaceutical Products
Passing off, a form of tort, the substantive law of which is based on common law with the object of protecting some form of property is no where defined in the Trade Marks Act, 1999 though is referred to in ss. 27(2), 134(1)(c) and 135.
India
14 Jun 2006
18
Product Patenting in the Indian Pharma Sector
In the recent times the Indian pharma sector has been marked by dynamic changes. The Patent Act of 1970 as amended on March 22, 2005 marked the end of a protected era and has brought in a new phase in the integration of India into the global pharmaceutical market.
India
14 Jun 2006
19
Novartis Denied Patent for Gleevec
Patents are available only for inventions that are novel, non-obvious as well as useful. Therefore, where novelty is a bedrock concept of all patent systems, nonobviousness is the ultimate condition of patentability but first of all an invention i.e. a product of investigation and experiment must qualify as an invention.
India
31 May 2006
Links to Result pages
 
1